Lin BioScience, Inc.

B-Cell Lymphoma Pipeline Expands with 300+ Therapies in Development for 2025

2 months ago

• DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area. • Several major pharmaceutical companies including BeiGene, Celgene, Hoffmann-La Roche, and Allogene Therapeutics have initiated pivotal late-stage clinical trials for novel B-cell lymphoma treatments in March 2025. • Emerging therapies include CAR-T cell approaches, bispecific antibodies, and novel targeted agents, with many incorporating dual-targeting mechanisms to overcome resistance seen with single-target therapies.

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

5 months ago

Lin BioScience's investigational drug LBS-007 has been granted Fast Track Designation by the U.S. FDA for treating acute myeloid leukemia, highlighting its potential to address unmet medical needs in acute leukemia treatment. The company is conducting a Phase 1/2 trial in patients with relapsed or resistant acute leukemias across the US, Australia, and Taiwan.